CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
Latest Information Update: 09 May 2024
At a glance
- Drugs Rucaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Registrational
- Acronyms CATCH-R
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 28 Mar 2024 This trial has been discontinued in Czechia, according to European Clinical Trials Database record.
- 12 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 11 Aug 2023 Status changed from recruiting to completed.